STUDY PROTOCOL

A double-blind randomized controlled trial to assess the effect of bright light therapy on depression in patients with Parkinson’s disease

Sonja Rutten1,2*, Chris Vriend1,2,3, Jan H. Smit1,3, Henk W. Berendse3,4, Adriaan W. Hoogendoorn1, Odile A. van den Heuvel1,2,3† and Ysbrand D. van der Werf2,3†

Abstract

Background: A disturbed circadian rhythm seems to be a causal factor in the occurrence of depressive disorders in patients with Parkinson’s disease (PD). The circadian rhythm can be restored with light. Therefore, Bright Light Therapy (BLT) might be a new treatment option for depression in PD patients.

Methods/design: In this double-blind controlled trial, 84 subjects with idiopathic PD are randomized to either BLT or a control light condition. The BLT condition emits white light with an intensity of 10,000 Lux, while the control device emits dim white light of 200 Lux, which is presumed to be too low to influence the circadian rhythm. Subjects receive 30 min of home treatment twice daily for three months. Timing of treatment is based on the individual chronotype. After finishing treatment, subjects enter a follow-up period of six months. The primary outcome of the study is the severity of depressive symptoms, as measured with the Hamilton Depression Rating Scale. Secondary outcomes are alternative depression measures, objective and subjective sleep measures, and salivary melatonin and cortisol concentrations. For exploratory purposes, we also assess the effects on motor symptoms, global cognitive function, comorbid psychiatric disorders, quality of life and caregiver burden. Data will be analyzed using a linear mixed models analysis.

Discussion: Performing a placebo-controlled trial on the effects of BLT in PD patients is challenging, as the appearance of the light may provide clues on the treatment condition. Moreover, fixed treatment times lead to an improved sleep-wake rhythm, which also influences the circadian system. With our study design, we do not compare BLT to placebo treatment, i.e. an ineffective control treatment. Rather, we compare structuring of the sleep-wake cycle in both conditions with additional BLT in the experimental condition, and additional dim light in the control condition. Participants are not informed about the exact details of the two light devices and the expected therapeutic effect, and expectancies are rated prior to the start of treatment. Ideally, the design of a future study on BLT should include two extra treatment arms where BLT and control light are administered at random times.

Trial registration: This trial was registered on ClinicalTrials.gov on May 17th 2012 (ClinicalTrials.gov Identifier: NCT01604876).

Keywords: Bright light therapy, Parkinson’s disease, Depressive disorder, Chronotherapy, Neuropsychiatry, Randomized controlled trial

* Correspondence: s.rutten@vumc.nl
† Equal contributors
1 Department of Psychiatry, VU University Medical Center/GGZ inGeest, A.J. Ernststraat 887, 1081 HL Amsterdam, The Netherlands
2 Department of Anatomy and Neurosciences, VU University Medical Center, Gustav Mahlerlaan 3004, 1000 MB Amsterdam, The Netherlands

© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
In patients with Parkinson's disease (PD), clinically relevant symptoms of depression occur in up to 35 %, with approximately 17 % fulfilling criteria for major depressive disorder (MDD) [1]. Depression has a major impact on overall functioning: depressed PD patients score lower on scales assessing activities of daily living, show a more rapid deterioration of motor and cognitive functioning, and have a higher mortality [2–4]. Depression is highly correlated with insomnia in PD [5–7], both contributing to a reduced quality of life in PD patients and their caregivers [3, 5].

Current treatment options for depression in PD are limited. Antidepressants can have side effects, such as orthostatic hypotension, sedation, and anticholinergic adverse effects, and may aggravate motor symptoms [8–10]. Cognitive behavioral therapy might be effective for the treatment of depression in PD patients, but has not been extensively studied yet [11]. To date, there are no evidence-based treatment options for insomnia in PD, and treatment with hypnotics can have adverse effects [7]. For patients with cognitive dysfunctions, which are common in PD [12], psychotherapy is not a always a feasible treatment option. An alternative treatment for depressive disorders and insomnia in PD patients is therefore needed.

Involvement of the circadian system in depression in PD
The circadian rhythm consists of neuroendocrine and behavioral cycles of approximately 24 h. This rhythm is generated by the 'biological clock,' the suprachiasmatic nucleus (SCN), which is located in the hypothalamic nucleus [13]. The SCN promotes wakefulness during the day and sleep during the night, providing the body with a pattern of rest and activity that corresponds to the day-night cycle. Moreover, the SCN is involved in mood regulation through the influence on neurotransmitter systems [14].

The circadian system regulates the secretion of several hormones, including melatonin and cortisol [15]. Under normal circumstances, the pineal gland starts secreting melatonin two to three hours prior to bedtime to promote sleep [15]. When plasma or saliva samples are taken under dim light conditions, this rise in melatonin levels is referred to as the dim-light melatonin offset (DLMO) [16]. In the morning, the secretion of melatonin is inhibited by exposure to light, leading to a decrease in melatonin concentrations [15]. Cortisol concentrations, on the other hand, peak in the morning, reflecting the response of the hypothalamic-pituitary-adrenal axis to awakening [15, 17]. This peak is referred to as the cortisol awakening response [18]. A more indirect measure of the circadian rhythm is the chronotype: the propensity of an individual to be active or asleep during a 24-hour period, with ‘morning’ and ‘evening types’ at the extremes of the spectrum. The chronotype can be measured with the Morningness–Eveningness Questionnaire (MEQ) [19]. Previous studies have shown a significant correlation between the MEQ score and the DLMO [19, 20].

Since the endogenous rhythm of the SCN is slightly different from the societal 24-hour day-night cycle, it has to be entrained by input signals from the environment called ‘zeitgebers,’ such as light, physical activity and food intake [13, 21]. Disrupting input to the biological clock can lead to a disturbed circadian rhythm, as reflected in a shift or change in amplitude of the cortisol and melatonin secretion patterns. A misalignment of the circadian rhythm is associated with depressive symptoms and insomnia [22–24].

PD patients are prone to desynchronization of the circadian rhythm, due to dopamine deficiency and conflicting input to the SCN [25]. Indeed, a disturbed circadian rhythm is observed in this population. Three studies described a phase advance of melatonin secretion in PD subjects [26–28]. Moreover, a decrease in the amplitude and total amount of melatonin and cortisol secretion has been observed [29, 30]. In another study, the pattern of cortisol secretion was also blunted, but total cortisol concentrations were increased in PD subjects compared to healthy controls [31]. These changes in melatonin and cortisol secretion patterns have also been reported in non-PD subjects with a depressive disorder or insomnia [32–34]. Based on these findings, we hypothesize that a disturbed circadian rhythm is involved in the pathophysiology of depression and insomnia in PD.

Bright light therapy
Light stimulates melanopsin-containing ganglion cells in the retina, providing the SCN with a 'daytime' signal via the retinohypothalamic tract [13]. Bright Light Therapy (BLT) therefore acts as a strong zeitgeber that can restore circadian rhythmicity. Light exposure in the morning advances the circadian rhythm and is effective in the treatment of depressive disorders [35–39], while evening light delays the rhythm and is thought to be more effective in the treatment of early awakening insomnia [32]. Since PD patients have an advanced circadian rhythm [26–28], evening light might be effective in treating not only insomnia, but also depressive symptoms in this population.

In their frequently cited meta-analysis, Golden et al. (2005) concluded that BLT is effective in the treatment of depression in non-PD samples [36]. Recent meta-analyses are more cautious in drawing conclusions on the efficacy of BLT due to limitations of the performed studies, e.g. small and heterogeneous study samples, short treatment duration and lack of a proper placebo condition [35, 37, 38]. The same issue was raised in a Cochrane review on the effects of BLT for treating insomnia in adults aged 60 years and older [40]. However, since treatment
effects of pharmacotherapy alone for these disorders are limited, and BLT is a low-cost treatment with a relatively high safety and tolerability [41], it is a treatment option that deserves further research.

In PD, the effects of BLT have been evaluated in two pilot studies [42, 43] and one retrospective, open label study [44]. These studies demonstrated positive effects on depressive symptoms, sleep and motor symptoms. However, depression was not the primary outcome measure in all studies, and all studies had methodological limitations. Therefore, further research on the efficacy of BLT in the treatment of PD patients with a depressive disorder is warranted.

**Methods**

This study aims to investigate whether BLT is more effective in reducing depressive symptoms in patients with PD and a depressive disorder, than a control light device. For secondary research purposes, we assess the effects of BLT on insomnia and circadian rhythmicity.

**Study design and procedures**

The design of this study is a double-blind randomized controlled clinical trial. An overview of all study procedures is given in Table 1.

After (self-)referral, subjects are sent an information package about the study. If still interested in participation after reading the additional information, prospective participants are screened by telephone by the first assessor (SR, psychiatry resident). When eligible, subjects are invited for an appointment with the first assessor. During this visit, subjects can ask any remaining questions. After providing written informed consent, subjects are randomized to the experimental or control condition by a research coordinator (CV), and baseline clinical assessments are performed. At the end of the visit, subjects are asked

---

### Table 1 Overview of study procedures

| STUDY PERIOD | ENROLLMENT and allocation | T-1 | T0 | T1 | T2 | T3 | T4 | T5 |
|--------------|---------------------------|-----|----|----|----|----|----|----|
| Time point   | weeks                    | −1  | −1 to 0 | 6 | 12 | 16 | 24 | 36 |
| ENROLMENT:   |                           |     |       |    |    |    |    |    |
| Eligibility screen |                       |    x |       |    |    |    |    |    |
| Informed consent  |                        |    x |       |    |    |    |    |    |
| Allocation   |                           |     |       |    |    |    |    |    |
| INTERVENTIONS:                               |                               |     |       |    |    |    |    |    |
| Experimental intervention |                   |       |       |    |    |    |    |    |
| Control intervention                           |       |       |    |    |    |    |    |
| ASSESSMENTS:                                   |       |       |    |    |    |    |    |
| HDRS         |                           | x   | x | x | x | x | x | x |
| GDS-30       |                           | x   | x | x | x | x | x | x |
| SCOPA-SLEEP  |                           | x   | x | x | x | x | x | x |
| CSD          |                           | x   | x | x | x | x | x | x |
| MEQ          |                           | x   | x | x | x | x | x | x |
| SCID-I       |                           | x   | x | x | x | x | x | x |
| UPDRS III and V |                         | x   | x | x | x | x | x | x |
| MMSE         |                           | x   | x | x | x | x | x | x |
| WHO-QOL      |                           | x   | x | x | x | x | x | x |
| ZBI          |                           | x   | x | x | x | x | x | x |
| CEQ          |                           | x   | x | x | x | x | x | x |
| Actigraphy   |                           | x   | x | x | x | x | x | x |
| Saliva sampling |                       | x   | x | x | x | x | x | x |
| Environmental light exposure |               | x   | x | x | x | x | x | x |

**Definitions of acronyms**

HDRS Hamilton Depression Rating Scale, GDS-30 30-item Geriatric Depression Scale, SCOPA-SLEEP Scales for Outcomes in Parkinson's Disease-Sleep, CSD Consensus Sleep Diary, MEQ Morningness-Eveningness Questionnaire, SCID-I Structured Clinical Interview for DSM-IV Axis I Disorders, UPDRS Unified Parkinson's Disease Rating Scale, MMSE Mini Mental State Examination, WHO-QOL-BREF World Health Organization Quality of Life assessment, abbreviated version; ZBI Zarit Burden Interview, CEQ Credibility/Expectancy Questionnaire.
to perform actigraphy, keep a sleep diary and wear a light sensor at home for the upcoming seven days. After this week, all baseline assessments are completed and a BLT or control device is installed at the subject’s home by the study coordinator or a trained research assistant. After a demonstration of the device, the three-month treatment phase starts. Clinical assessments are repeated halfway (T1) and at the end of treatment (T2). After completing treatment, subjects enter a six-month follow-up phase. Subsequent interventions are allowed within the follow-up phase, since we consider it unethical to withhold treatment from patients with remaining depressive symptoms. Follow-up assessments take place one (T3), three (T4) and six months (T5) after completing treatment. Prior to each follow-up assessment, subjects receive a package containing questionnaires, a sleep diary, actigraphy watch, light sensor and cotton dental rolls for saliva sampling, to perform these measures at home in the week prior to the assessment visit.

Randomization and blinding
To maintain blinding of the assessors, the research coordinator (CV) performs block randomization. Blocks are generated per season to rule out seasonal influences on the treatment effect. Both subjects and assessors are blinded for the treatment condition. To prevent unblinding, subjects are asked not to share any details of their treatment with their assessor. When patients do reveal their condition, the assessor is immediately replaced by the blinded project’s principle investigator (OvdH, psychiatrist).

Participants
Participants for this study are recruited throughout the Netherlands by various strategies, including referral by a neurologist, psychiatrist or other medical professional, recruitment through media of various associations involved with PD, and advertisement in a Dutch national newspaper.

Patients are eligible for inclusion when they are diagnosed with idiopathic PD by a neurologist. In addition, they are required to meet criteria of a major depressive disorder as classified by the DSM-IV [45]. Patients with a bipolar disorder are excluded due to the risk of inducing (hypo)mania with BLT [38]. We also exclude subjects with a current psychosis, due to the potential influence on our assessments and the risk of noncompliance. Finally, we exclude patients with a (relative) contraindication for BLT, such as a disorder associated with photosensitization reactions to light, e.g. porphyria, macular degeneration, retinal dystrophy, or lupus erythematosus, or when they have used pharmacological agents with a photosensitizing effect within the past four weeks [20]. Because changes in the use of antiparkinsonian or psychiatric medication might influence assessments, participants have to be on a stable dose of medication for at least four weeks before inclusion. Moreover, subjects and their physicians are asked not to change the medication regime during the treatment phase of the trial, unless this is deemed medically necessary.

Intervention
The experimental condition consists of BLT with a Brazil® Lightbox (Lumie, Cambridge, United Kingdom). This BLT device emits white, broad spectrum light. During treatment sessions, subjects are instructed to take place in front of the device at a distance of 30 cm, at which the intensity of the light is 10,000 Lux. To create a credible control condition, neutral density filters (Lee Filters, type 209.03ND, Hampshire, United Kingdom) are installed in the light device, so that the experimental and control device have an identical appearance when switched off. These filters reduce transmission uniformly, giving the light a dim white appearance. Subjects are instructed to position themselves at a distance of 40 cm from the control device, at which the light intensity is approximately 200 Lux. At this light intensity, which is lower than in a dimly lit room, no substantial effect on circadian rhythm is expected [46].

Subjects in both conditions follow the treatment at home for a period of three months. Subjects use the device both in the morning and the evening. Treatment duration per session is 30 min, which is sufficient to entrain the SCN at an intensity of 10,000 Lux [20]. Timing of the morning treatment session is based on the score on the MEQ [19, 41].

Since evening BLT should be administered at least 90 min prior to bedtime [20], the evening session takes place 9. Five hours prior to the morning BLT, in order to allow eight hours of nighttime sleep. To increase user convenience and compliance, the device is attached to a timer, so that the device switches on automatically at the times set for treatment.

Outcomes
Primary outcome measure
The primary outcome measure of this study is the change in depressive symptoms as regards to baseline, as measured with the 17-item version of the Hamilton Depression Rating Scale (HDRS) [47], from baseline (T0) to the end of treatment (T2).

Secondary outcome measures
Our secondary outcome measures are (1) alternative depression measures, (2) subjective and objective quality of sleep, and (3) circadian rhythmicity. Since we are mainly interested in the direct and long-term treatment effects, all outcome measures described below concern the difference between the treatment groups in the change in outcome measures as regards to the baseline value between i)
baseline and the end of follow-up (T0 to T5).

1. Additional depression measures:
The change in HDRS-score between T0 and T5 is considered as a secondary outcome measure. As an alternative measure for depression, we use the Geriatric Depression Scale (GDS-30) [48], a self-report instrument. The GDS-30 does not contain items regarding somatic symptoms of depression, and might therefore have a higher diagnostic specificity in PD [48]. As a third depression measure, we assess the proportion of subjects in each treatment group that achieves complete remission at T2 and T5, i.e. fulfilling DSM-IV criteria of a ‘depressive disorder in full remission’, as determined with the Structured Clinical Interview for DSM-IV Axis I disorders (SCID-I) [49].

2. Sleep:
   a. Subjective experience of sleep is measured with the Scales for Outcomes in Parkinson’s Disease-Sleep (SCOPA-SLEEP) [50], a validated self-report instrument that contains two subscales: one rating nighttime sleep disturbances and one on excessive daytime sleepiness. Both subscale scores are used as a secondary outcome measure.
   b. Sleep patterns are objectified by actigraphy, which is considered to be a valid alternative for polysomnography in the quantitative evaluation of sleep in PD patients [51]. Subjects are asked to wear an actigraphy device (GENEActiv Sleep; GENEActiv, Huntingdon, United Kingdom) on their non-dominant wrist continuously for seven consecutive days. Sleep parameters are calculated in two steps. First, accelerometer data is preprocessed with GENEActive PC software version 2.2, using reports of time of attempted sleep and time of final awakening from the Consensus Sleep Diary (CSD) [52]. Second, the raw GENEActive accelerometer data are converted into Actiwatch counts, as described by Te Lindert et al. (2013), to calculate sleep parameters. The sleep parameters of main interest are total sleep time and sleep fragmentation, i.e. the number of wake bouts per night.

3. Circadian rhythmicity:
   In this study, we use salivary concentrations of melatonin and cortisol as markers for the circadian rhythm. At each time point in the study, subjects are instructed to collect saliva at home during a single day, using cotton dental rolls (Salivette®, Sarstedt, Numbrech, Germany). The first saliva sample is taken immediately after waking up, followed by three more samples at an interval of 30 min. In the evening, subjects start hourly collection of samples four hours prior to intended bedtime. Samples are preserved in the refrigerator by the patient, and collected by the researchers one or two days later. They are centrifuged and stored at −80 °C until all samples of one subject that are collected throughout the study can be analyzed simultaneously. The cortisol concentration in the saliva samples is determined by on-line solid-phase extraction liquid chromatography tandem mass spectrometry (XLS-MS/MS), which is preferred over immunoassays to prevent cross-reactivity with other corticosteroids [53]. We will calculate the area under the curve with respect to the ground (AUCG) and the area under the curve with respect to the index of salivary cortisol change over time (AUCI), as described by Pruessner et al. (2003) [54]. The AUCG is an estimate of the total cortisol secretion throughout the day, whereas the AUCI is a measure of the cortisol awakening response. The AUCG and AUCI of the salivary cortisol concentrations of the morning samples are considered as a secondary outcome measure. We will also report the cortisol concentration in the first saliva sample taken as a measure of the endpoint of pre-awakening increase in cortisol [17]. The melatonin concentrations are assessed in the evening saliva samples using liquid chromatography tandem mass spectrometry (LS-MS/MS). We will calculate the DLMO with the ‘hockey-stick method’, as described by Danilenko et al. (2013) [55].

Assessments for exploratory purposes
For exploratory purposes, we assess the difference between the treatment groups in the absolute change in the following outcome measure from T0 to T2 and T0 to T5.

1. Subjective quality of sleep, rated in the CSD on a scale ranging from 0 (very poor) to 4 (very good).
2. Sleep efficiency as objectified with actigraphy. Sleep efficiency is defined as the percentage of time the subject spent asleep between onset of sleep and getting up in the morning.
3. Evening cortisol secretion, calculated as both the AUCG and AUCI.
4. Global cognitive function, assessed with the Mini Mental State Examination (MMSE) [56].
5. Presence of comorbid psychiatric disorders, as determined with the SCID-I.
6. Severity of motor symptoms, using section III of the Unified Parkinson’s Disease Rating Scale (UPDRS) [57]. The UPDRS-III is rated by the first assessor, who is trained by a movement disorder specialist (HB).
7. The chronotype, as determined with the MEQ.
8. Quality of life, as measured with the abbreviated version of the World Health Organization Quality of Life assessment (WHOQOL-BREF) [58].
9. Caregiver burden, as reported by the caregiver on the Zarit Burden Interview (ZBI) [59].

**Covariates**

In order to control for factors that might influence the association between treatment and the outcome measures, we collect the following additional data:

1. Medication use:
   Current medication use is reviewed at each assessment. Since dopaminergic agents can have a positive influence on mood in PD patients with depressive symptoms [60], we will control for the total dose of dopaminomimetics, which is converted to a levodopa equivalent daily dose using the conversion rate described by Olde Dubbelink et al. (2013) [61]. Moreover, we will correct for the initiation or change in dosage of antidepressants or sleep medication.
2. Exposure to environmental light:
   We collect data on the exposure to environmental light using a light sensor (Actiwatch Light®, Cambridge Neurotechnology Ltd., Cambridge UK). Subjects are asked to continuously wear the sensor on the outer layer of their clothing for seven consecutive days. Raw data on light exposure is preprocessed with Actiwatch Activity & Sleep Analysis 5 software, after which total amount of light exposure during the day is calculated using custom-made in-house software.
3. Expectancy
   In a previous study on BLT, a positive correlation between expectations and treatment response was found [62]. In this study, we assess the expectancies of our subjects with the Credibility/Expectancy Questionnaire (CEQ) [63], after installation of the device at home.
4. Compliance:
   Compliance with treatment is assessed with an occupancy data logger (HOBO® occupancy/light logger) that is attached to the device. The logger detects the time and duration of presence of the participant in front of the device. Treatment session compliance is defined as exposure to the device for at least 70 % of the prescribed duration, i.e. 21 out of 30 min, within the set time frame. Total compliance is calculated as the proportion of sessions that a subject is compliant with therapy. We assess the effects of total compliance on the intervention effect, as well as compliance with morning and evening therapy separately.

**Side effects and treatment satisfaction**

Prior to the start of the trial, we made an overview of potential adverse effects that subjects might experience during treatment, based on previous reports [41, 64]. One week after the start of treatment, subjects are contacted by telephone by the research assistant to inquire about these side effects. At assessment visit T1, patients are also screened for side effects. We will report the difference in prevalence of reported side effects between both groups.

After completing the treatment phase, all patients are asked to rate their appreciation of timing and duration of therapy sessions on a visual analogue scale (VAS). Moreover, they indicate on a VAS the extent to which they would like to continue treatment after the end of the trial. We will report average VAS scores as an indicator of treatment satisfaction per group.

**Statistical analysis**

**Sample size calculation**

Prior to the start of the study, we calculated the necessary sample size for a sufficient power at the end of treatment (T2) in a mixed models analysis. We aimed to have sufficient sensitivity for a minimal standardized effect size of Cohen’s $d = 0.6$, with an estimated standard deviation of 1.0 and intra-subject correlation of assessments of $\rho = 0.6$. For a statistical power of 80 % and a two-tailed significance level of $p < 0.05$, 35 subjects per treatment group were required. To correct for a maximum drop-out of 20 %, we would need 7 additional subjects per group, resulting in a total sample size of 84 subjects.

**Efficacy analysis**

Analyses will be performed on the Modified-Intent-To-Treat population, which consists of all subjects randomized in the trial who received at least one week of light treatment and provided at least one post-baseline assessment of the HDRS. As a sensitivity analysis, we will compare the baseline characteristics to the Intent-to-Treat population, i.e. all subjects who were randomized in the trial. To assess the effect of treatment duration, we will also assess the effects in the Per Protocol-population, i.e. all subjects who completed the three months treatment duration.

Demographics and clinical characteristics of both the BLT and control group at baseline will be presented with percentages or mean scores with standard deviations. Correlations between continuous variables at baseline will be calculated using Pearson’s correlation coefficients.

The effect of the intervention on the change from T0 to T2, and from T0 to T5, in outcome measures will be assessed using a linear mixed-effects model analysis with assessment visit as the lowest level, and patient as
highest level. Time of assessment will be handled as a categorical variable. The effect of the intervention on the outcome measures over time will be modeled by an intervention by time interaction with two degrees of freedom. In all analyses, we will correct for baseline values of the outcome variable. In addition, we will assess whether adding the covariates to the regression model leads to a significant change of the regression coefficient of the condition effect of ≥10%.

No imputation of missing values will be performed, since linear mixed models handle missing data by placing the data in long format, where the available data of each measurement is nested within persons.

Discussion
Performing a placebo-controlled trial on the effects of BLT is challenging, since the appearance of the device or the characteristics of the emitted light can provide the subject with clues about the treatment condition. This can influence the subject's expectancies of the treatment, which has been shown to impact on the outcomes of a study on BLT the past [62]. Deactivated negative ionizers, dim red light and light boxes with full-band filters were used as control light conditions for BLT in previous studies [37, 65]. In this trial, we also use a light device with full-band filter. However, the reduced intensity of the light could point out that the subjects in the control condition were not receiving BLT. Therefore, subjects' expectancies are rated prior to the start of treatment, and participants are not informed about the exact details of the two light devices and their expected therapeutic effect. Although this might raise ethical questions, it is a valid way to guarantee subject blinding when studying a treatment that lacks a credible placebo condition. Therefore, this study did receive approval of the ethics committee. Moreover, the subjects in the control condition do receive some form of treatment. All subjects in our study are required to use the light device at fixed times in the morning and the evening, imposing a fixed sleep-wake structure on all participants. According to the 'social zeitgeber' hypothesis of Ehlers et al. (1988), a disruption of social rhythms can induce a depressive episode through disturbance of the circadian rhythm [66]. Restoring the circadian rhythm by re-establishing daily routines, including time of awakening and going to bed, might therefore have a positive influence on mood [66]. Since all participating subjects in our study achieve a more regular sleep-wake cycle, we feel that subjects in the control condition are not completely deprived of treatment. Moreover, a report by Zeiter et al. (2000) suggests that dim light of approximately 100 lux also has the ability to cause a shift in circadian rhythm [67]. Although the healthy volunteers participating in this study were exposed to the light for 6.5 h [67], we cannot rule out the possibility that 30 min of exposure to 200 lux of light will influence the circadian system of PD patients.

With our study design, we do not compare BLT to ‘pure’ placebo treatment, i.e. an ineffective control treatment. Rather, we compare structuring of the sleep-wake cycle through set treatment times in both conditions, with additional BLT in the experimental condition, and additional dim light in the control condition. In order to be able to assess the effects of BLT only, a future study on the effects of BLT on depression in PD would have two additional treatment arms, where BLT and control light are administered at random times. Moreover, more research is needed on the timing (morning or evening) and duration of BLT, as well as the influence of light intensity. However, we hypothesize that with the design of this study, we will still find a greater improvement on depression, insomnia and biomarkers of circadian rhythm in the subjects in our experimental condition as compared to our control subjects, due to the addition of BLT to the imposed sleep-wake structure.

Abbreviations
AUC<sub>C</sub>: Area under the curve with respect to the ground; AUC<sub>T</sub>: And area under the curve with respect to the index of salivary cortisol change over time; BLT: Bright light therapy; CAR: Cortisol awakening response; CEQ: Credibility/Expectancy Questionnaire; CSD: Consensus Sleep Diary; DLMO: Dim-light melatonin onset; DSM-IV: Diagnostic Statistical Manual, fourth edition; GDS-30: 30-item Geriatric Depression Scale; HDRS: Hamilton Depression Rating Scale; LS-MS/MS: Liquid chromatography tandem mass spectrometry; MDD: Major depressive disorder; MEQ: Morningness-Eveningness Questionnaire; MMSE: Mini Mental State Examination; PD: Parkinson’s disease; RCT: Randomized controlled trial; SCID-I: Structured Clinical Interview for DSM-IV Axis I Disorders; SCN: Suprachiasmatic nucleus; SCOPA-SLEEP: Scales for Outcomes in Parkinson’s Disease-Sleep; UPDRS: Unified Parkinson’s Disease Rating Scale; WHO-QOL-BREF: World Health Organization Quality of Life assessment, abbreviated version; XLS-MS/MS: On-line solid-phase extraction liquid chromatography tandem mass spectrometry; ZBI: Zarit Burden Interview

Acknowledgements
The authors want to acknowledge Eus van Someren for his consulting role in the design of the study.

Funding
This study was funded by Hersenstichting Nederland (Fellowship F2011(1)-03 to dr. van den Heuvel), Stichting Parkinson Fonds (to drs. van der Werf/van den Heuvel) and Parkinson Vereniging (to drs. van den Heuvel/Van der Werf). These funding bodies had no role in the design of the study, collection, analysis, and interpretation of data or in writing the manuscript.

Availability of data and materials
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Further information or requests for collaboration related to the study design are available from the corresponding author on reasonable request.

Authors’ contributions
SR, CV, JS, HB, OvdH and YvdW all made substantial contributions to the design of the study and critically revised the manuscript. SR provided local project coordination, collected data as first assessor, performed data analysis and interpretation, and drafted the manuscript. CV performed randomization and installed the light devices, made substantial contributions to data analysis. AH revised the statistical analysis plan and made substantial contributions to data analysis and interpretation. YvdW obtained funding, and installed the light devices in absence of CV. OvdH obtained funding, provided supervision of the overall project coordination and collected data as second assessor when SR was unblinded or absent. All authors read and approved the final manuscript.
Competing interests
Light devices were supplied by Lumie (Cambridge, United Kingdom). Lumie had no role in the design of the study, collection, analysis, and interpretation of data or in writing the manuscript.

Consent for publication
Not applicable.

Ethics approval and consent to participate
This study was approved by the ethic committee of the VU University medical center (VUMc; study number 2012/75). All subjects provided written informed consent before inclusion. Quality and safety of the study, as described in the Good Clinical Practice Guidelines (GCP), was guaranteed through monitoring by the Clinical Research Board of the VUMc and GCP training of all researchers.

Author details
1. Department of Psychiatry, VU University Medical Center/GGG inGeest, A.J. Ernstraat 887, 1081 HL Amsterdam, The Netherlands. 2. Department of Anatomy and Neurosciences, VU University Medical Center, Gustav Mahlerlaan 3004, 1000 MB Amsterdam, The Netherlands. 3. Department of Neuroscience, de Boelelaan 1085, 1081 HV Amsterdam, The Netherlands. 4. Department of Neurology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands.

Received: 12 August 2016 Accepted: 24 September 2016
Published online: 21 October 2016

References
1. Reijnders J, Ehr U, Weber W, Aarsland D, Leentjens A. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008;23:183–9.
2. Schrag A, Janshahmehr A, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2008;79:308–12.
3. Aarsland D, Pahlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease: epidemiology, mechanisms and management. Nat Rev Neurol. 2012;8:35–47.
4. Karlsen KH, Lohsoonthorn V, Ilkovic Z, Alonso A, Mayo R, Carswell A. Circadian phase position. J Biol Rhythms. 1999;14:227–36.
5. Caap-Athgren M, Delin O. Insomnia and depressive symptoms in patients with Parkinson’s disease: relationship to health-related quality of life. An interview study of patients living at home. Arch Gerontol Geriatr. 2001;32:23–31.
6. Menza M, Dobkin RD, Marini H. Free-running sleep in Parkinson’s disease. Mov Disord. 2010;25 Suppl 1:S117–118.
7. Madhusoodanan S, Alexeenko L, Sanders R, Brenner R. Estrapyrhamidal symptoms associated with antidepressants—a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry. 2010;22:148–56.
8. Richard H, McDermott MP, Kurlan R, Lysim JM, Como PG, Pearson N, Factor SA, Juncos J, Semano Ramos C, Brodsky M, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012;78:1292–9.
9. Vajda FJ, Solinas C. Current approaches to management of depression in Parkinson’s Disease. J Clin Neurosci. 2005;12:739–43.
10. Bomasang-Layno E, Fadlon I, Murray A, Himelhoch S. Antidepressive treatments for Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2015;21:833–42.
11. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012;11:697–707.
12. Rosemanner AM. Functional neuroanatomy of sleep and circadian rhythms. Brain Res Rev. 2009;61:281–306.
13. McClung C. Circadian genes, rhythms and the biology of mood disorders. Parmacol Ther. 2007;114:222–32.
14. Benloucif S, Burgess H, Klerman E, Lewy A, Middleton B, Murphy P, Parry B, Revell V. Measuring melatonin in humans. J Clin Sleep Med. 2008;4:66–9.
15. Lewy A, Cutler N, Sack R. The endogenous melatonin profile as a marker for circadian phase position. J Biol Rhythms. 1999;14:227–36.
16. Sadler T, Kirschaum C, Kudelka B, Adam E, Pruessner J, Wüst S, Dockray S, Smyth N, Evans P, Hellhamer D, et al. Assessment of the cortisol awakening response: Expert consensus. Psychoneuroendocrinology. 2016;63:414–22.
17. Pruessner J, Wolf O, Hellhamer D, Buske-Kirschbaum A, von Auer K, Jobst S, Kapers F, Kirschbaum C. Free cortisol levels after awakening: a reliable biological marker for the assessment of adrenocortical activity. Life Sci. 1997;61:2539–49.
18. Horne JA, Ostberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol. 1976;4:97–110.
19. Wirz-Justice A, Benedetti F, Terman M. Chronotherapeutics for affective disorders. Basel: Karger; 2009.
20. Welsh DK, Logothetis DE, Meister M, Reppert SM. Individual neurons dissociated from rat suprachiasmatic nucleus express independently phased circadian firing rhythms. Neurosci. 1995;14697–706.
21. Monteleone P, Maj M. The circadian basis of mood disorders: recent developments and treatment implications. Eur Neuropsychopharmacol. 2008;18:701–11.
22. Cajochen C, Munch M, Knoblauch V, Blatter K, Wirz-Justice A. Age-related changes in the circadian and homeostatic regulation of human sleep. Chronobiol Int. 2006;23:461–74.
23. Wirz-Justice A. Diurnal variation of depressive symptoms. Dialogues Clin Neurosci. 2008;10:337–43.
24. Rutten S, Wiering R, van den Heuvel OA, Smit JH, Berendse HW, van der Werf YD. Bright light therapy in Parkinson’s disease: an overview of the background and evidence. Parkinsons Dis. 2012;2012:767105.
25. Bordet R, Devos D, Brique S, Toulout Y, Gueud J, Libera C, Deste A. Study ofcircadian melatonin secretion pattern at different stages of Parkinson’s disease. Clin Neuropharmacol. 2003;26:655–72.
26. Fertl E, Auff E, Doppelbauer A, Waldhauser F. Circadian secretion pattern of melatonin in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1991;54:41–7.
27. Fertl E, Auff E, Doppelbauer A, Waldhauser F. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. J Neurol Neurosurg Psychiatry. 1993;5:227–34.
28. Hartmann A, Veldhuis J, Bueseisch M, Standhardt H, Heuser I. Twenty-four hour cortisol release profiles in patients with Alzheimer’s and Parkinson’s disease compared to normal controls: utradian secretory pulsatility and diurnal variation. Neurobiol Aging. 1997;18:265–9.
29. Vidovic A, Nobles C, Reid K, Peng J, Turek F, Marconi A, Rodmaker A, Simuni T, Zadkoff C, Zee P. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson’s disease. JAMA. 2014;311:463–9.
30. Skogar Ó, Fall P-A, Hallgren G, Lök K, Bringer B, Carlsson M, Lennartsson U, Sandbjörk H, Tomhage C-J. Diurnal salivary cortisol concentrations in Parkinson’s disease: increased total secretion and morning cortisol concentrations. Int J. Gen Med. 2011;4:561–9.
31. Lack L, Wright H. Treating chronobiological components of chronic insomnia. Sleep Med. 2007;8:637–44.
32. Sriwisesa V, Smith M, Spence W, Lowe A, Kayumov L, Pandi-Perumal S, Parry B, Cardinali D. Melatonin in mood disorders. World J Biol Psychiatry. 2006;7:138–51.
33. Vreeburg PJ, Hoogendijk WJ, van Pelt J, Denk RH, Verhagen JC, van Dyck R, Smit JH, Zitman FG, Penninx BW. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch Gen Psychiatry. 2009;66:617–26.
34. Even C, Schröder C, Friedman S, Rouillon F. Efficacy of light therapy in nonseasonal depression: a systematic review. J Affect Disord. 2008;108:11–23.
35. Golden RN, Glynes BN, Ekstrom RD, Hamer RM, Jacobsen FM, Suppes T, Wisner KL, Nemeroff CB. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry. 2005;162:656–62.
36. Mårtensson B, Pettersson A, Berglund L, Ekelskul L. Bright white light therapy in depression: A critical review of the evidence. J Affect Disord. 2015;182:1–7.
37. Tuunanen A, Kripke D, Endo T. Light therapy for non-seasonal depression. Cochrane database Syst Rev. 2004;CD004050.
38. Terman J, Terman M, Lo E-S, Cooper T. Circadian time of morning light administration and therapeutic response in winter depression. Arch Gen Psychiatry. 2001;58:69–75.
39. Montgomery P, Dennis J. Bright light therapy for sleep problems in adults aged 60+. Cochrane database Syst Rev. 2002;CD003403.
58. Skevington SM, Lotfy M, O’Connor E. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and developments in Parkinson’s disease. Rev Neurosci. 2012;23:199–226.

59. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: Author; 2000.

60. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, TTolosa E, Weintraub D. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;2010:573–80.

61. Olde Dubbelink KT, Stoffers D, Deijen JB, Twisk JW, Stamm CJ, Berendse HW. Cognitive decline in Parkinson’s disease is associated with slowing of resting-state brain activity: a longitudinal study. Neurobiol Aging. 2013;34:408–18.

62. Knappen S, van de Werken M, Gordijn M, Meesters Y. The duration of light treatment and therapy outcome in seasonal affective disorder. J Affect Disord. 2014;166:343–6.

63. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000;31:73–86.

64. Kogan AO, Guilford PM. Side effects of short-term 10,000-lux light therapy. Am J Psychiatry. 1998;155:293–4.

65. Most El, Scheltens P, van Someren EJ. Prevention of depression and sleep disturbances in elderly with memory-problems by activation of the biological clock with light—a randomized clinical trial. Tràls. 2010;11.

66. Ehlers C, Frank E, Kupfer D. Social zeitgebers and biological rhythms. A unified approach to understanding the etiology of depression. Arch Gen Psychiatry. 1988;45:948–52.

67. Zeitzer J, Dijk DJ, Kronauer R, Brown E, Czeisler C. Sensitivity of the human circadian pacemaker to nocturnal light: melanin phase resetting and suppression. J Physiol. 2000;526:695–702.

Submit your next manuscript to BioMed Central and we will help you at every step:

• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit